PROTALIX BIOTHERAP.DL-01
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also dev… Read more
Market Cap & Net Worth: PROTALIX BIOTHERAP.DL-01 (PBDA)
PROTALIX BIOTHERAP.DL-01 (F:PBDA) has a market capitalization of $158.50 Million (€154.41 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #17417 globally and #1812 in its home market, demonstrating a -21.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PROTALIX BIOTHERAP.DL-01's stock price €1.92 by its total outstanding shares 80421181 (80.42 Million).
PROTALIX BIOTHERAP.DL-01 Market Cap History: 2015 to 2026
PROTALIX BIOTHERAP.DL-01's market capitalization history from 2015 to 2026. Data shows change from $741.30 Million to $158.50 Million (-13.51% CAGR).
PROTALIX BIOTHERAP.DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PROTALIX BIOTHERAP.DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PBDA by Market Capitalization
Companies near PROTALIX BIOTHERAP.DL-01 in the global market cap rankings as of March 19, 2026.
Key companies related to PROTALIX BIOTHERAP.DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PROTALIX BIOTHERAP.DL-01 Historical Marketcap From 2015 to 2026
Between 2015 and today, PROTALIX BIOTHERAP.DL-01's market cap moved from $741.30 Million to $ 158.50 Million, with a yearly change of -13.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €158.50 Million | +28.86% |
| 2025 | €123.00 Million | -14.00% |
| 2024 | €143.02 Million | +7.01% |
| 2023 | €133.65 Million | +35.59% |
| 2022 | €98.56 Million | +68.17% |
| 2021 | €58.61 Million | -74.82% |
| 2020 | €232.79 Million | +21.55% |
| 2019 | €191.52 Million | -19.72% |
| 2018 | €238.57 Million | -47.45% |
| 2017 | €454.03 Million | +21.68% |
| 2016 | €373.13 Million | -49.67% |
| 2015 | €741.30 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of PROTALIX BIOTHERAP.DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $158.50 Million USD |
| MoneyControl | $158.50 Million USD |
| MarketWatch | $158.50 Million USD |
| marketcap.company | $158.50 Million USD |
| Reuters | $158.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.